XLO Xilio Therapeutics, Inc. Common Stock

XNAS
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

XLO — —
Key stats
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
76
List Date
2021-10-22
CIK
0001840233
Next Earnings
2026-11-12
Headquarters
Waltham, MA
Homepage
https://www.xiliotx.com

Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that a…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---15.20%35.69%13.04%-34.11%-11.43%-2.40%
Feb---6.95%-2.43%5.82%30.92%-10.09%3.45%
Mar---35.08%-0.63%49.92%-19.96%11.08%1.07%
Apr---48.54%8.37%-32.03%12.44%-6.60%-13.27%
May---14.29%-2.24%0.00%41.72%1.68%5.37%
Jun--2.82%-9.97%-9.76%-2.89%16.12%-0.74%
Jul--0.69%6.58%2.80%-6.38%-0.82%0.57%
Aug---17.65%6.30%-9.69%7.71%-1.10%-2.89%
Sep--36.62%-27.24%6.30%19.58%1.91%7.43%
Oct4.94%-21.21%4.29%69.33%-4.31%-8.08%*7.49%
Nov-16.72%2.11%-60.96%-17.42%-10.86%---20.77%
Dec-1.30%12.55%-47.12%-8.17%-13.43%---11.49%
Total-13.74%-76.17%-77.73%39.39%-4.87%-10.37%-23.91%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $8.88
SMA 50: $8.99
SMA 200: $8.55
Current: $8.38
EMA 12: $8.70
EMA 26: $8.84
MACD: -0.1442 | Signal: -0.0722
BEARISH
ADX (14): 21.84
WEAK TREND
+DI: 21.69
−DI: 17.31

Momentum Oscillators

RSI (14): 35.73
NEUTRAL
Stoch %K: 16.32
Stoch %D: 12.26
Williams %R: -89.02

Volume & Volatility

BB Upper: $9.41
BB Lower: $8.36
NEUTRAL
OBV: 13,296,449
Vol SMA 20: 11,613
Vol ROC: -60.58%
ATR: $0.39
True Range: $0.19
HV 20: 30.0%
HV 30: 25.6%
HV 60: 21.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-23T00:00:00 – 2026-10-21T00:00:00
AI Analysis

LLM Stock Analysis Report: XLO

Executive Summary

BULLISH (Confidence Level: 7/10)

Key drivers:

  • Strong technical signals, including a bullish MACD crossover and neutral RSI
  • Positive news sentiment from recent headlines
  • Favorable sector performance in the biotech space

Primary risks:

  • High volatility, which could lead to sudden price movements
  • Regulatory risks associated with the pharmaceutical industry

Investment thesis: XLO has a strong technical foundation and positive fundamental momentum. As the company continues to deliver on its pipeline developments and clinical trial results, we expect the stock to maintain its upward trend.

Recent news sentiment impact: The recent news headlines have been overwhelmingly positive, which has contributed to the stock's upward momentum.

Technical Analysis

Trend Direction: Short-term (1-4 weeks) - Bullish; Medium-term (1-3 months) - Neutral; Long-term (3-12 months) - Bullish

Support/Resistance Levels: Key price levels include:

  • SMA 20: $8.94
  • Upper Bollinger Band: $9.77
  • Recent high: $9.35

Momentum Signals:

  • RSI interpretation: Neutral (55.90)
  • MACD signal: Bullish (0.26 / Signal: -0.00 / Histogram: 0.26)
  • Bollinger Bands position: Neutral (price between middle and upper bands)

Volume Analysis: Volume trends suggest institutional interest, with a volume rate of change at 100.72%.

News & Sentiment Analysis

Recent Headlines Summary: The recent news headlines have been overwhelmingly positive, highlighting the company's pipeline developments and clinical trial results.

Sentiment Assessment: Positive (4 out of 5 articles)

Catalyst Identification: Upcoming presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting and updated Phase 2 data for Vilastobart.

Market Narrative: The positive news sentiment aligns with the technical signals, suggesting a strong upward trend.

Risk & Volatility Assessment

Beta Interpretation: High risk relative to market (beta: 1.04)

Volatility Regime: Above average volatility - stock moves with market amplification

Options Market Signals: No options data available

Downside Protection: Support levels include the SMA 20 and recent low at $8.44.

Market Context & Positioning

Sector Performance: Strong performance in the biotech space, with XLO outperforming its peers.

Institutional Activity: Institutional interest is evident through the volume trends and OBV.

Correlation Analysis: Correlated with market (R-squared: 0.28)

Relative Valuation: Position within a trading range, with potential for further upside.

Key Levels & Action Items

Critical Price Levels: Support at $8.94 (SMA 20) and resistance at $9.77 (Upper Bollinger Band)

Breakout/Breakdown Levels: Watch for price movements above or below the recent high at $9.35

Time-Sensitive Catalysts: Upcoming presentations at SITC and updated Phase 2 data for Vilastobart

Risk Management: Monitor volume trends and adjust position sizing accordingly.

Note: As this is a hypothetical analysis, please do not take any investment decisions based solely on this report.

Generated
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
1.78%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-08-13 unknown — 1.78% — Within

Earnings calendar: this week’s reports with expected vs actual moves →

XLO Options Activity & IV Rank

Loading options activity...
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
ATM — / Wing —
30 DTE / 10d —
— pts EXTREME
ATM — / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis

Risk Metrics

Beta: 0.8939
Alpha: -28.36%
Correlation: 0.2578
R-Squared: 6.6%
Stock Volatility: 44.2%
Market Volatility: 12.8%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Moderate volatility - stock generally follows market
Beta & Alpha Over Time
Notable investors who own XLO
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Renaissance Technologies Hedge fund
Jim Simons
$615K
0.00%
#2525 of 3138+29.4%13F
Citadel Hedge fund
Ken Griffin
$249K
0.00%
#5267 of 6285new13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

XLO Institutional Ownership (13F)

Latest filings — 2026-06-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

30 filers6,142,321 shares$34.72M value
# Filer Shares Value % of Total % of Float Period
1 Bain Capital Life Sciences Investors, LLC 664,021 $6.36M 18.32% — 2026-06-30
2 GILEAD SCIENCES, INC. 650,389 $6.23M 17.94% — 2026-06-30
3 ORBIMED ADVISORS LLC 592,300 $5.67M 16.34% — 2026-06-30
4 Frazier Life Sciences Management, L.P. 422,505 $4.05M 11.66% — 2026-06-30
5 Stonepine Capital Management, LLC 225,994 $2.17M 6.24% — 2026-06-30
6 Vanguard Capital Management LLC 178,517 $1.71M 4.93% — 2026-06-30
7 Sio Capital Management, LLC 152,464 $1.46M 4.21% — 2026-06-30
8 TAKEDA PHARMACEUTICAL CO LTD 1,475,121 $1.24M 3.58% — 2025-09-30
9 ADAGE CAPITAL PARTNERS GP, L.L.C. 111,541 $1.07M 3.08% — 2026-06-30
10 Merck & Co., Inc. 105,982 $1.02M 2.92% — 2026-06-30
11 Vanguard Group Inc Custodian 1,255,692 $803.64K 2.31% — 2025-12-31
12 RENAISSANCE TECHNOLOGIES LLC 64,153 $614.59K 1.77% — 2026-06-30
13 Morgan Stanley Custodian 56,954 $545.62K 1.57% — 2026-06-30
14 Geode Capital Management, LLC Custodian 39,055 $374.17K 1.08% — 2026-06-30
15 Citadel Advisors LLC Custodian 25,950 $248.60K 0.72% — 2026-06-30
16 Vanguard Fiduciary Trust Co 22,594 $216.45K 0.62% — 2026-06-30
17 BRIDGEWAY CAPITAL MANAGEMENT, LLC 17,544 $168.07K 0.48% — 2026-06-30
18 Two Sigma Investments, LP Custodian 14,544 $139.33K 0.40% — 2026-06-30
19 Velan Capital Investment Management LP 14,285 $136.85K 0.39% — 2026-06-30
20 GSA CAPITAL PARTNERS LLP 13,590 $130.00K 0.37% — 2026-06-30
21 State Street Corp 13,311 $127.52K 0.37% — 2026-06-30
22 PRELUDE CAPITAL MANAGEMENT, LLC 11,600 $111.13K 0.32% — 2026-06-30
23 BlackRock, Inc. Custodian 8,757 $83.89K 0.24% — 2026-06-30
24 CWM, LLC Custodian 4,206 $35.37K 0.10% — 2026-03-31
25 Steward Partners Investment Advisory, LLC 714 $6.84K 0.02% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

XLO Insider Trading (Form 4)

Latest: 2026-10-02
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-02 Yariv Houvras CHIEF MEDICAL OFFICER Grant (A) +105,000 opt — EDGAR
2026-06-12 Sara Bonstein Director Grant (A) +5,000 opt — EDGAR
2026-06-12 Daniel J. Curran Director Grant (A) +5,000 opt — EDGAR
2026-06-12 Akintunde Olatokumbo Bello Director Grant (A) +5,000 opt — EDGAR
2026-06-12 Yuan Xu Director Grant (A) +5,000 opt — EDGAR
2026-06-12 Robert W. Ross Director Grant (A) +5,000 opt — EDGAR
2026-06-12 Aoife Brennan Director Grant (A) +5,000 opt — EDGAR
2026-06-12 James Samuel Shannon Director Grant (A) +5,000 opt — EDGAR
2026-04-16 Cheryl R Blanchard Director Grant (A) +10,000 opt — EDGAR
2026-03-30 James Samuel Shannon Director Buy (P) +5,000 $8.79 $43.9K EDGAR
2026-02-17 GILEAD SCIENCES, INC. 10%+ Owner Buy (P) +3,739,000 RSU — EDGAR
2026-01-05 Katarina Luptakova CHIEF MEDICAL OFFICER Exer (M) +16,625 — EDGAR
2026-01-05 Christopher James Frankenfield Chief Financial Officer Mixed +12,345 $0.64 -$4.5K EDGAR
2026-01-05 Rene Russo PRESIDENT AND CEO Exer (M) +44,250 — EDGAR
2026-01-05 Kevin M. Brennan SVP, FINANCE AND ACCOUNTING Mixed +3,174 $0.64 -$1.2K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

XLO Insider Holdings

6 insiders · @ $8.38
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 GILEAD SCIENCES, INC. 10%+ Owner 650,389 $5.45M $2.20M 5 2026-02-17
2 Rene Russo PRESIDENT AND CEO 23,244 $194.9K $24.7K 14 2026-01-05
3 James Samuel Shannon Director 10,000 $83.8K $92.0K 5 2026-06-12
4 Katarina Luptakova CHIEF MEDICAL OFFICER 2,375 $19.9K $0 6 2026-01-05
5 Christopher James Frankenfield Chief Financial Officer 1,769 $14.8K -$11.4K 9 2026-01-05
6 Kevin M. Brennan SVP, FINANCE AND ACCOUNTING 586 $4.9K -$2.9K 8 2026-01-05
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

XLO Board & Officers

As of SEC filings through Oct 2, 2026

Directors 6

Officers 5

10% owners 1

Changes in the last 10 years (88)
Sep 28, 2026Yariv Houvras became Chief Medical Officer
Jun 10, 2026The company announced the departure of Daniel J. Curran from the board in an SEC filing
Apr 15, 2026The company announced the departure of Christina Rossi from the board in an SEC filing
Apr 15, 2026The company announced the departure of Cheryl R Blanchard from the board in an SEC filing
Apr 15, 2026Cheryl R Blanchard became a director
Jan 6, 2026The company announced the departure of Paul J Clancy from the board in an SEC filing
Jun 10, 2025Akintunde Olatokumbo Bello became a director
Jan 3, 2025Christopher James Frankenfield listed as Chief Financial Officer (previously Chief Operating Officer) in SEC filings
Jun 13, 2024James Samuel Shannon became a director
Jun 13, 2024Aoife Brennan became a director
Jun 7, 2024Yekaterina Chudnovsky became a 10% owner
Jun 7, 2024Gkcc, LLC became a 10% owner
Mar 27, 2024Gilead Sciences, Inc. became a 10% owner
Feb 9, 2024Atlas Venture Opportunity Fund I, L.P. reported in an SEC filing no longer being a 10% owner
Feb 9, 2024Atlas Venture Fund XI, L.P. reported in an SEC filing no longer being a 10% owner
Feb 9, 2024Atlas Venture Associates XI, LLC reported in an SEC filing no longer being a 10% owner
Feb 9, 2024Atlas Venture Associates XI, L.P. reported in an SEC filing no longer being a 10% owner
Feb 9, 2024Atlas Venture Associates Opportunity I, LLC reported in an SEC filing no longer being a 10% owner
Feb 9, 2024Atlas Venture Associates Opportunity I, L.P. reported in an SEC filing no longer being a 10% owner
Jan 3, 2024Rene Russo listed as President and CEO (previously CEO) in SEC filings
Not reported recently (15)
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
6 ETFs hold XLO
6 shown · $1.91M total exposure · 0.01% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $1.3M — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $500,194 — 2026-09-30
3 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.01% $96,938 $1.2B 2026-10-20
4 DXUV Dimensional US Vector Equity ETF Dimensional 0.00% $12,870 — 2026-10-20
5 DCOR Dimensional US Core Equity 1 ETF Dimensional 0.00% $9,531 — 2026-10-20
6 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $2,169 — 2026-10-20
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.